DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» PLK3
PLK3
Subtype and Pathway Specific Responses to Anticancer Compounds in Breast Cancer
ERCC6L Promotes Cell Growth and Invasion in Human Colorectal Cancer
Androgen Receptor
Inhibition of ERK 1/2 Kinases Prevents Tendon Matrix Breakdown Ulrich Blache1,2,3, Stefania L
PRODUCTS and SERVICES Target List
The Role of Plk3 in Oncogenesis
Polo-Like Kinase 3 Is Required for Entry Into S Phase
The Pyrazolyl-Urea Gege3 Inhibits Tumor Angiogenesis and Reveals Dystrophia Myotonica Protein Kinase (DMPK)1 As a Novel Angiogenesis Target
Lestaurtinib
Specific Inhibition of HIF Activity
Discovery of Potent and Selective MRCK Inhibitors with Therapeutic
Supplement Materials Table S1. the Top15 Terms for Genetic Association
Online Supplement to Gene Expression Pathways Across
Hu Antigen R Regulates Antiviral Innate Immune Responses Through the Stabilization of Mrna for Polo-Like Kinase 2
Blood Transcriptomics to Characterize Key Biological Pathways and Identify Biomarkers for Predicting Mortality in Melioidosis
Kinases That Are Currently Stored in the Phospho.ELM Database
PLK3, Active (SRP5291)
Connectivity Map Analysis Indicates PI3K/Akt/Mtor Inhibitors As Potential Anti-Hypoxia Drugs in Neuroblastoma
Top View
The Plk3-Cdc25 Circuit
Differential Regulation of Polo-Like Kinase 1, 2, 3, and 4 Gene Expression in Mammalian Cells and Tissues
Supporting Information for “A High-Throughput Targeted Proteomic Approach for Comprehensive
Kin-2787, Is Active in Class Ii and Class Iii Braf Mutant Models
Pyrimidin-2-Amine Derivatives As PLK4 Inhibitors for T
Phosphorylation of PLK3 Is Controlled by Protein Phosphatase 6
Radiosensitizing Effect of Novel Phenylpyrimidine Derivatives on Human Lung Cancer Cells Via Cell Cycle Perturbation S
Single Kinase Substrate Peptides
In Vitro and in Vivo Activity of R547: a Potent and Selective Cyclin-Dependent Kinase Inhibitor Currently in Phase I Clinical Trials
Aurora B Kinase Promotes CHIP-Dependent Degradation of Hif1a in Prostate Cancer Cells Kuntal Biswas1, Sukumar Sarkar1, Neveen Said1, David L
In Silico Investigation of the Anti-Tumor Mechanisms of Epigallocatechin-3-Gallate
Identification of Polo-Like Kinase 1 As a Potential Therapeutic Target in Anaplastic Thyroid Carcinoma
Polo-Like Kinase 3 Functions As a Tumor Suppressor and Is a Negative Regulator of Hypoxia-Inducible Factor-1A Under Hypoxic Conditions
Dysregulation of KRAS Signaling in Pancreatic Cancer Is Not Associated with KRAS Mutations and Outcome
PSMA7 and PLK3 Are Promising Druggable Targets for Treating
In Vitro Biological Activity of a Novel Small-Molecule Inhibitor of Polo-Like Kinase 1
Cell Cycle Kinases As Therapeutic Targets for Cancer
Polo‑Like Kinase 3 Inhibits Osteosarcoma Cell Proliferation and Tumorigenesis Via Cooperative Interaction with P21